Japan's Otsuka ends pacts with Acucela after trial failure


Tokyo-based Otsuka Pharmaceutical scrapped two licensing deals with ophthalmic biotech Acucela following disappointing Phase III results for the venture's lead candidate, ACU-4429 (emixustat), which is being developed to treat dry age-related macular degeneration, a serious eye condition that can cause blindness.

A pact between Otsuka and Tokyo-listed Acucela dating to 2008 had the two firms working jointly on development and commercialization efforts for the candidate that targeted the RPE65 enzyme to reduce the accumulation of retinoid-related toxic metabolites.

But ACU-4429 missed its primary endpoint in a U.S. Phase IIb/III trial of 508 patients, according to data released last month. It failed to show any significant difference in a once-daily regimen compared to a placebo.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

"Following a review of the clinical trial data, Otsuka decided to end its participation in further development activities for ACU-4429 and informed Acucela of its decision to terminate the agreement upon the lapse of a pre-determined notification period," the company said in a statement. 

Acucela raised more than $160 million in 2014 in Japan via an initial public offering, allowing the firm headed by Japanese eye specialist Ryo Kubota to straddle operations between its Seattle headquarters in the U.S. and Japan.

The other candidate in the collaboration, OPA-6566, was developed by the Japanese firm to treat glaucoma under a 2010 pact. But this collab will also now be axed.

"In addition, Otsuka simultaneously informed Acucela of its decision to end their collaboration for OPA-6566 for glaucoma, exercising its contractual right to terminate the agreement upon the lapse of a pre-determined notification period," Otsuka said. "The two companies originally signed a co-development and co-commercialization agreement for the compound in September 2010. Otsuka OPA-6566 is in development in the U.S., where a Phase I/II clinical trial has been completed."

Otsuka was not immediately available to comment on future plans for OPA-6566.

- here's the release


Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.